A 2017 Phase II clinical trial of nivolumab, a PD‐L1 immune checkpoint inhibitor, in patients with MMRd and MSI‐H CRC who had received at least three rounds of prior therapy and were no longer responsive to first‐line treatments found that this therapy provided durable response and disease control in these patients. This evidence concerns the gene CD274 and colorectal carcinoma.